Significance of Salivary Gland Radioiodine Retention on Post-ablation (131)I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma

Abstract

PURPOSE: We investigated whether (131)I whole-body scintigraphy could predict functional changes in salivary glands after radioiodine therapy. METHODS: We evaluated 90 patients who received initial high-dose (>/=3.7 GBq) radioiodine therapy after total thyroidectomy. All patients underwent diagnostic (DWS) and post-ablation (TWS) (131)I whole-body scintigraphy. Visual assessment of salivary radioiodine retention on DWS and TWS was used to divide the patients into two types of groups: a DWS+ or DWS- group and a TWS+ or TWS- group. Salivary gland scintigraphy was also performed before DWS and at the first follow-up visit. Peak uptake and %washout were calculated in ROIs of each gland. Functional changes (Deltauptake or Deltawashout) of salivary glands after radioiodine therapy were compared between the two groups. RESULTS: Both peak uptake and the %washout of the parotid glands were significantly lower after radioiodine therapy (all p values <0.001), whereas only the %washout were significantly reduced in the submandibular glands (all p values <0.05). For the parotid glands, the TWS+ group showed larger Deltauptake and Deltawashout after radioiodine therapy than did the TWS- group (all p values <0.01). In contrast, the Deltauptake and Deltawashout of the submandibular glands did not significantly differ between the TWS+ and TWS- groups (all p values >0.05). Likewise, no differences in Deltauptake or Deltawashout were apparent between the DWS+ and DWS- groups in either the parotid or submandibular glands (all p values >0.05). CONCLUSION: Salivary gland radioiodine retention on post-ablation (131)I scintigraphy is a good predictor of functional impairment of the parotid glands after high-dose radioiodine therapy.